Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02787616 · ClinicalTrials.gov registry record
Genetic Basis of Rosacea
A clinical trial of Rosacea, sponsored by Stanford University.
- Completed
- Registry status
- 306
- Enrollment target
- 1
- Study location
NCT02787616: Completed study of Rosacea, sponsored by Stanford University.
NCT02787616 is a study of Rosacea that has completed, run by Stanford University. The registered enrollment target is 306 participants, above the 230-participant average among 23 other Rosacea trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02787616, a study of Rosacea, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 306 participants
- Enrollment target
- 1
- Study location
Study Summary
Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. The purpose of this study is to develop gene expression profiles of papulopustular rosacea compared to those of normal skin. The investigators hope to better understand the abnormal gene functions that might contribute to this condition. This understanding may lead to the development of additional and better treatments for rosacea.
Conditions Studied
Interventions
- GENETIC buccal swab
Study Locations (1)
California
- Stanford Dermatology - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2012-04-13 |
| Est. Completion | 2018-11-16 |
What the finished NCT02787616 record still lists
NCT02787616 is an observational study that tracks outcomes without assigning an intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap, above the 230-participant average among 23 other Rosacea trials with a reported enrollment target (33% higher).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which buccal swab is the first listed.
NCT02787616 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02787616 about?
NCT02787616 is a clinical study titled "Genetic Basis of Rosacea". Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. The purpose of this study is to deve...
What is the current status of trial NCT02787616?
This trial is currently completed. The enrollment target is 306 participants. The study started on 2012-04-13. Estimated completion is 2018-11-16.
What conditions does trial NCT02787616 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT02787616?
The interventions under investigation include: buccal swab (GENETIC).
Who is sponsoring clinical trial NCT02787616?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02787616 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02787616's enrollment target sits among peer trials
306 7th of 23 higher than 17 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
Analysis of the Microbiome in Rosacea
ACTIVE NOT RECRUITING · Early Phase 1
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
-
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
- NCT06057337 · 306 participants · NA
Families With Pride ("Familias Con Orgullo").
- NCT06498635 · 306 participants · Phase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI